Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International ...
– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid …